Blair William & Co. IL Sells 7,264 Shares of Rocket Pharmaceuticals, Inc. $RCKT

Blair William & Co. IL trimmed its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 6.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 104,211 shares of the biotechnology company’s stock after selling 7,264 shares during the period. Blair William & Co. IL owned 0.10% of Rocket Pharmaceuticals worth $255,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its position in shares of Rocket Pharmaceuticals by 24.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 995,690 shares of the biotechnology company’s stock worth $6,641,000 after acquiring an additional 192,905 shares in the last quarter. Rhumbline Advisers raised its position in shares of Rocket Pharmaceuticals by 8.4% in the 1st quarter. Rhumbline Advisers now owns 107,638 shares of the biotechnology company’s stock worth $718,000 after acquiring an additional 8,299 shares in the last quarter. PFG Investments LLC bought a new position in shares of Rocket Pharmaceuticals in the 1st quarter worth $89,000. Farther Finance Advisors LLC raised its position in shares of Rocket Pharmaceuticals by 7,818.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 13,540 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 13,369 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Rocket Pharmaceuticals in the 1st quarter worth $251,000. 98.39% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Elisabeth Bjork bought 10,000 shares of the stock in a transaction dated Wednesday, August 27th. The shares were purchased at an average price of $3.41 per share, for a total transaction of $34,100.00. Following the completion of the purchase, the director directly owned 40,000 shares of the company’s stock, valued at $136,400. This represents a 33.33% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Militello sold 28,918 shares of the company’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $3.96, for a total value of $114,515.28. Following the completion of the sale, the insider owned 67,006 shares in the company, valued at $265,343.76. The trade was a 30.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,368 shares of company stock worth $221,675 over the last ninety days. 24.76% of the stock is owned by corporate insiders.

Rocket Pharmaceuticals Stock Down 7.3%

Rocket Pharmaceuticals stock opened at $3.71 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.39 and a current ratio of 6.39. The business’s 50-day simple moving average is $3.31 and its two-hundred day simple moving average is $4.04. The company has a market cap of $400.32 million, a PE ratio of -1.48 and a beta of 0.60. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $18.89.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). During the same period in the previous year, the firm posted ($0.74) earnings per share. Equities analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Canaccord Genuity Group reduced their price target on Rocket Pharmaceuticals from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, July 25th. Needham & Company LLC reissued a “hold” rating on shares of Rocket Pharmaceuticals in a research report on Thursday, July 24th. Leerink Partners reduced their price target on Rocket Pharmaceuticals from $9.00 to $7.00 and set a “market perform” rating for the company in a research report on Friday, October 3rd. Chardan Capital reaffirmed a “buy” rating and set a $11.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, October 14th. Finally, Bank of America raised Rocket Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $4.00 to $10.00 in a research report on Wednesday, August 20th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $16.67.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.